423 related articles for article (PubMed ID: 11998607)
1. Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tiuxetan.
Hendrix CS; de Leon C; Dillman RO
Clin J Oncol Nurs; 2002; 6(3):144-8. PubMed ID: 11998607
[TBL] [Abstract][Full Text] [Related]
2. The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL).
Bischof Delaloye A
Leuk Lymphoma; 2003; 44 Suppl 4():S29-36. PubMed ID: 15154740
[TBL] [Abstract][Full Text] [Related]
3. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
Marcus R
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
[TBL] [Abstract][Full Text] [Related]
4. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
5. Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin's lymphoma.
Micallef IN
Clin Lymphoma; 2004 Oct; 5 Suppl 1():S27-32. PubMed ID: 15498147
[TBL] [Abstract][Full Text] [Related]
6. Ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Johnston PB; Bondly C; Micallef IN
Expert Rev Anticancer Ther; 2006 Jun; 6(6):861-9. PubMed ID: 16761929
[TBL] [Abstract][Full Text] [Related]
7. Logistics of therapy with the ibritumomab tiuxetan regimen.
Meredith RF
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S35-8. PubMed ID: 16979437
[TBL] [Abstract][Full Text] [Related]
8. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunotherapy for non-Hodgkin's lymphoma: a review for radiation oncologists.
Macklis RM; Pohlman B
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):833-41. PubMed ID: 16965871
[TBL] [Abstract][Full Text] [Related]
10. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA
J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300
[TBL] [Abstract][Full Text] [Related]
11. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
Wagner HN; Wiseman GA; Marcus CS; Nabi HA; Nagle CE; Fink-Bennett DM; Lamonica DM; Conti PS
J Nucl Med; 2002 Feb; 43(2):267-72. PubMed ID: 11850494
[TBL] [Abstract][Full Text] [Related]
12. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma.
Witzig TE
Drugs Today (Barc); 2004 Feb; 40(2):111-9. PubMed ID: 15045033
[TBL] [Abstract][Full Text] [Related]
13. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma.
Wiseman GA; Witzig TE
Cancer Biother Radiopharm; 2005 Apr; 20(2):185-8. PubMed ID: 15869453
[TBL] [Abstract][Full Text] [Related]
14. Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature.
Ansell SM; Schilder RJ; Pieslor PC; Gordon LI; Emmanouilides C; Vo K; Czuczman MS; Witzig TE; Theuer C; Molina A
Clin Lymphoma; 2004 Dec; 5(3):202-4. PubMed ID: 15636698
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies conjugated with radioisotopes for the treatment of Non-Hodgkin's lymphoma.
Bush S
Semin Oncol Nurs; 2002 Feb; 18(1 Suppl 1):16-21. PubMed ID: 11878047
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma.
Witzig TE
Semin Oncol; 2003 Dec; 30(6 Suppl 17):11-6. PubMed ID: 14710398
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Riley MB; Gordon LI
Semin Oncol Nurs; 2004 Feb; 20(1 Suppl 1):8-13. PubMed ID: 15160856
[TBL] [Abstract][Full Text] [Related]
18. Nursing a patient during and after 90Y-ibritumomab tiuxetan (Zevalin) therapy.
Clayton J
Leuk Lymphoma; 2003; 44 Suppl 4():S49-55. PubMed ID: 15154742
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice.
Hagenbeek A
Leuk Lymphoma; 2003; 44 Suppl 4():S37-47. PubMed ID: 15154741
[TBL] [Abstract][Full Text] [Related]
20. Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
Meredith RF
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S23-9. PubMed ID: 16979435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
